Published Erratum Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2025 Jun 9:118228. doi: 10.1016/j.biopha.2025.118228 Q17.52025

Corrigendum to "The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells" [Biomed. Pharmacother. 176 (2024) 116892]

关于“使用酪氨酸激酶受体抑制剂和老药联合疗法靶向患者来源的胶质母细胞瘤干细胞”一文的勘误[Biomed. Pharmacother. 176 (2024) 116892] 翻译改进

Malgorzata Kucinska¹, Julia Pospieszna², Jing Tang³, Natalia Lisiak⁴, Ewa Toton⁴, Blazej Rubis⁴, Marek Murias²

作者单位 +展开

作者单位

¹ Department of Toxicology, Poznan University of Medical Sciences, 3 Rokietnicka Street, Poznan 60-806, Poland. Electronic address: kucinska@ump.edu.pl.

² Department of Toxicology, Poznan University of Medical Sciences, 3 Rokietnicka Street, Poznan 60-806, Poland.

³ Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki 00290, Finland.

⁴ Department of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, 3 Rokietnicka Street, Poznan 60-806, Poland.

DOI: 10.1016/j.biopha.2025.118228 PMID: 40494675

摘要中英对照阅读

Keywords：correction; combination therapy; tyrosine kinase inhibitors; repurposed drugs; glioblastoma stem cells

关键词：校正; 联合疗法; 酪氨酸激酶抑制剂; 老药新用; 胶质母细胞瘤干细胞

相关内容

期刊名：Biomedicine & pharmacotherapy

缩写：BIOMED PHARMACOTHER

ISSN：0753-3322

e-ISSN：1950-6007

IF/分区：7.5/Q1

文章目录更多期刊信息

全文链接

官方链接

PMC全文

引文链接

复制

已复制！

格式：

Corrigendum to "The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells" [Biomed. Pharmacother. 176 (2024) 116892]

关于“使用酪氨酸激酶受体抑制剂和老药联合疗法靶向患者来源的胶质母细胞瘤干细胞”一文的勘误[Biomed. Pharmacother. 176 (2024) 116892] 翻译改进

The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells

针对源自胶质母细胞瘤干细胞的酪氨酸激酶受体抑制剂和老药联合治疗

The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy

一种使用CUSP9策略的九种再定位药物对胶质母细胞瘤干细胞进行协同药理学阻断的有效性研究

ImmuneOncology-tyrosine kinase inhibitors combination, sometimes less is more

免疫肿瘤学：有时联合酪氨酸激酶抑制剂，量少效果好

Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells

Copanlisib联合ABL酪氨酸激酶抑制剂对抗费城染色体阳性耐药细胞的联合疗法

The future of tyrosine kinase inhibitors: single agent or combination?

酪氨酸激酶抑制剂的未来：单药治疗还是联合用药？

Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics

瑞德西韦及其与已知药物联合用于治疗COVID-19

Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors

克服对第一代表皮生长因子受体酪氨酸激酶抑制剂耐药性的分子机制

Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinemia: a retrospective cohort study

PD-1抑制剂联合酪氨酸激酶抑制剂治疗合并高胆红素血症的晚期肝细胞癌患者的疗效及安全性：一项回顾性队列研究

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer

HER2阳性乳腺癌联合治疗中的酪氨酸激酶抑制剂